177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer

Summary

This study employed an open-label, non-randomized design, representing the first human trial of its kind. It utilized a standard 3+3 dose-escalation approach, focusing on patients with metastatic castration-resistant prostate cancer, initiating treatment at a dose of 1.85 GBq over a 6-week period. Subsequent cohorts underwent sequential 50% dose escalations until the observation of dose-limiting toxicity (DLT).

Timeline

Start

2023-05-01

Primary completion

2025-04-01

Completion

2025-10-01

Publications

• Yang H, Wang J, Wen X, Guo H, Jakobsson V, Zhao T, Zeng F, Shen H, Zhang H, Liu X, Qin Y, Li X, Xiong H, Zhou Z, Zhang J, Chen X. Dansylated Amino Acid-Modified Long-Acting PSMA Derivatives 68Ga/177Lu-LNC1011 as Prostate Cancer Theranostics. J Nucl Med. 2025 May 1;66(5):739-747. doi: 10.2967/jnumed.124.268959.

Drugs

Indications